As previously announced on February 17, 2011, the Company received a notice from the Staff of the NYSE Amex (the "Amex") that the Company was not in compliance with Section 704 of the Amex Company Guide which required the Company to hold its 2010 Annual Stockholders' Meeting no later than December 31, 2010. The Company was given until March 21, 2011 to submit a plan to regain compliance with this requirement. The delay in holding the 2010 Meeting resulted from the time required to respond to comments the Company had received from the SEC related to the SEC's review of the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2009. The specific comments causing the delay related to the Company's accounting treatment of the May 2009 warrants discussed above. Despite the Company's best efforts to resolve the matter to allow the annual meeting to be held by December 31, 2010, final resolution of the SEC staff's accounting comments did not occur until mid-February 2011. The Company immediately filed an amended and restated 2009 10-K, amended and restated quarterly reports on Form 10-Q for the first three quarters of 2010 and its definitive proxy statement for the 2010 Meeting. The 2010 Stockholders' Meeting was held on March 17, 2011. As a result on March 23, 2011, the Company received formal notification from the Amex that "the Company has resolved the continued listing deficiency referenced in the NYSE Amex LLC's letter dated February 17, 2011".About Hemispherx Biopharma Hemispherx Biopharma, Inc. is an advanced specialty pharmaceutical company engaged in the manufacture and clinical development of new drug entities for treatment of seriously debilitating disorders. Hemispherx's flagship products include Alferon N Injection® (FDA approved for a category of sexually transmitted diseases) and the experimental therapeutics Ampligen® and Alferon® LDO. Ampligen® is an experimental RNA nucleic acid being developed for globally important debilitating diseases and disorders of the immune system. Hemispherx's platform technology includes components for potential treatment of various severely debilitating and life threatening diseases. Hemispherx has patents comprising its core intellectual property estate and a fully commercialized product (Alferon N Injection®). The Company wholly owns and exclusively operates a GMP certified manufacturing facility in the United States for commercial products. For more information please visit www.hemispherx.net . Information contained in this news release, other than historical information, should be considered forward-looking and is subject to various risk factors and uncertainties. For instance, the strategies and operations of Hemispherx involve risk of competition, changing market conditions, change in laws and regulations affecting these industries and numerous other factors discussed in this release and in the Company's filings with the Securities and Exchange Commission. Any specifically referenced investigational drugs and associated technologies of the Company (including Ampligen® and Alferon® LDO) are experimental in nature and as such are not designated safe and effective by a regulatory authority for general use and are legally available only through clinical trials with the referenced disorders. The forward-looking statements represent the Company's judgment as of the date of this release. The Company disclaims, however, any intent or obligation to update these forward-looking statements. The planning, completion, results or submission of clinical trials do not imply that any study product will ever be approved commercially for the studied or other treatment indications. Similarly, the resumption of commercial sales of Alferon N Injection® is predicated on certain technical achievements and acceptance by FDA of resulting data reports, which may or may not occur. Similarly, the new diagnostic initiatives of the Company in CFS may not be validated in wider clinical trials and thus may not be accepted by the FDA as a basis for evaluating the potential efficacy of Ampligen®.
CONTACT: Company/Investor Contact: Dianne Will Hemispherx Biopharma, Inc. 518-398-6222 email@example.com